Synthesis of human [9-leucine-B] Insulin

Chemical synthesis of [des(tetrapeptide B27--30), Tyr(NH2)26-B] and [des(pentapeptide B26--30), Phe(NH2)25-B] bovine insulins

Two analogs of bovine insulin, [des(tetrapeptide B27--30), Tyr(NH2)26-B] and [des(pentapeptide B26--30), Phe(NH2)25-B] insulin, which differ from the parent molecule in that the C-terminal tetrapeptide and pentapeptide sequences, respectively, from the B chain have been eliminated and the newly exposed residues are amidated, have been synthesized. The [des(tetrapeptide B27--30), Tyr(NH2)26-B] insulin shows potencies of 16.8 IU/mg by the mouse convulsion assay method and 10.8 IU/mg by the radioimmunoassay method. The [des(pentapeptide B26--30), Phe(NH2)25-B] insulin possesses a potency of 10.5 IU/mg when assayed by the mouse convulsion method and 14 IU/mg by the radioimmunoassay technique. The potencies of these analogs are higher than the potencies of the respective non-amidated derivatives (Katsoyannis et al., 1973, 1974). It is speculated that the gradual decline of biological activity observed as amino acid residues are eliminated from the C-terminal region of the B chain of insulin is due to the proximity of a hydrophilic carboxyl group to the hydrophobic core of the protein molecule.

Interaction between the A2 and A19 amino acid residues is of critical importance for high biological activity in insulin: [19-leucine-A]insulin

The replacement of tyrosine at position A19 by leucine in the insulin molecule led to an analogue, [19-leucine-A]insulin [( Leu19-A]insulin), displaying insignificant receptor binding affinity and in vitro biological activity less than 0.1 and 0.05%, respectively, compared to the natural hormone. This analogue along with the previously reported [2-glycine-A]-, [2-alanine-A]-, and [2-norleucine-A]insulins is the least potent insulin analogue we have examined. Circular dichroic studies showed that all these analogues are monomeric at concentrations at which insulin is primarily dimeric. We conclude that an aromatic ring at position A19 and the presence of the side chain of isoleucine at position A2 are each of critical importance for high biological activity in insulin. It appears that the van der Waals interaction between the side chain of isoleucine A2 and tyrosine A19, present in crystalline insulin, is among the most important determinants for high biological activity in insulin.

Nature of the B10 amino acid residue. Requirements for high biological activity of insulin

Human [10-asparagine-B] insulin ([ Asn10 -B] insulin), an analogue which differs from the parent molecule in that the histidine residue at position 10 of the B chain (B10) is replaced by asparagine, has been synthesized and isolated in purified form. In vitro biological assays indicated a potency of ca. 35% compared to insulin. We have previously shown that the replacement of histidine at position B10 by lysine resulted in an analogue displaying ca. 15% of the biological activity of natural hormone, while the substitution of leucine in this position produced a molecule exhibiting ca. 45% potency in in vivo assays. The data indicate that molecular size of the amino acid residue at position B10 may be important in the maintenance of a structure commensurate with high biological activity. Polarity at this position appears to be rather unimportant while a strongly basic group appears to be deleterious.

Critical role of the A2 amino acid residue in the biological activity of insulin: [2-glycine-A]- and [2-alanine-A]insulins

We report the synthesis of [2-glycine-A]insulin ([ Gly2 -A]insulin) and [2-alanine-A]insulin ([ Ala2-A]insulin) in which the indicated amino acid has been substituted for isoleucine found in this position in the natural hormone. The circular dichroic (CD) spectra of the analogues were obtained, and their properties were examined in several biological assays. CD studies suggested that the analogues remain monomeric at concentrations at which insulin is partly or mostly dimeric. Both analogues are extremely weak full agonists. [ Gly2 -A]-insulin displays 0.05% of the potency of bovine insulin, whereas [Ala2-A]insulin assays at 0.4% of the activity of the natural hormone. We conclude that the presence of the side chain of isoleucine at position A2 is a critical requirement for high biological activity in insulin. The data, together with previous observations, are discussed in connection with an interaction between the side chain of isoleucine-A2 and the phenolic ring system of tyrosine-A19, which are in van der Waals contact in crystalline insulin. This interaction may be required to permit the molecule to assume a conformation consistent with dimerization and with binding to the insulin receptor.

An insulin analogue possessing higher in vitro biological activity than receptor binding affinity. [21-Proline-B]insulin

To study the effect of an increase in the potential for beta-turn formation of the B20-B23 segment of the B-chain moiety on the biological behavior of insulin, the [21-proline-B]insulin [( Pro21-B]insulin) was synthesized. The in vitro biological activity and the receptor binding affinity of this analogue were compared with that of insulin. In stimulating labeled glucose incorporation into lipids in rat fat cells, the analogue displayed 33.2% potency relative to insulin; receptor binding affinity for the analogue was 15.9% in rat liver membranes and 17.8% in isolated fat cells. [Pro21-B]insulin is thus the first example of a modified insulin for which the biological activity exceeds the receptor binding potency. The secondary structure of this analogue was investigated by circular dichroism studies. Although no significant differences in the conformation of monomeric insulin and analogue could be discerned, their difference in behavior with respect to dimerization and biological properties indicates that these forms are not equivalent. We suggest that the intrinsic activity of receptor-bound [Pro21-B]insulin is greater than that of insulin, although the receptor displays greater affinity for insulin than for the analogue. We consider a model for the interaction between insulin and its receptor that accommodates our findings.

[12-asparagine-B] human insulin. An analogue with modification in the hydrophobic core of insulin

The human [12-Asparagine-B] insulin [Asn12-B] insulin) which differs from the parent molecule in that the valine residue at position B12 is substituted by an asparagine residue, has been synthesized by the procedures developed in this laboratory. In stimulating glucose oxidation and lipogenesis the analogue exhibited potencies of 0.19% and 0.14%, respectively, as compared to insulin. In insulin receptor binding [Asn12-B] insulin was found to possess a potency of ca. 0.29% compared to the natural hormone. At high concentrations this analogue is shown to have the same maximal activity in the in vitro assays as the natural hormone. This indicates that despite the low affinity for of the analogue for the insulin receptor, the analogue-receptor complex is fully capable of initiating the series of chemical events that leads to the biological response. It is concluded that the B12 valine contributes greatly in the maintenance of a structure possessing the proper receptor-binding characteristics, but does not have any role in modulating the activity of the hormone-receptor complex. The potency of this analogue by radioimmunoassay is at least 100-fold higher than the in vitro biological assays, indicating that the immunological determinants of insulin can be essentially unrelated to the biological activity of the molecule.

Radioimmunoassay of chemically modified insulins

The reactions between four insulin antisera and eighteen insulin derivatives with modifications at the A1, B1 and B29 positions have been studied using a standard double-antibody radioimmunoassay procedure. The derivatives studied had: a) single modifications at A1, B1 or B29,; b) modifications at two sites with or without a crosslink between them; c) modifications at all three sites with or without a crosslink. Analysis of the results showed a clear difference in the reactivity of the antisera. One antiserum (GP5) was highly sensitive to modifications of the B1 residue and another (Ab1) was sensitive to A1 and B29 modifications. Thus, immunological potencies of insulin analogues derived on the basis of these reactions with the antisera give widely varying results. These antisera were used in discriminatory radioimmunoassays of chemically modified insulins in biological fluids for estimation of in vivo hypoglycaemic potencies by an infusion technique, where the knowledge of the specificity of the antisera was useful in assessing the immunological identity of immunoreactive material in plasma with the analogue infused.

Synthesis of des(tetrapeptide B(1-4)) and des(pentapeptide B(1-5)) human insulins. Two biologically active analogues

Two analogues of human insulin, des(tetrapeptide B(1-4))-and des (pentapeptide B(1-5))-insulin, which differ from the parent molecule in that the N-terminal tetrapeptide and pentapeptide sequences, respectively, have been eliminated, have been synthesized. The des(tetrapeptide B(1-4))-insulin shows potencies of 13 IU/mg by the mouse convulsion assay method and 7.6 IU/mg by the radioimmunoassay method. The des(pentapeptide B(1-5))-insulin possesses a potency of 1.2 IU/mg when assayed by the glucose-oxidation method in isolated fat cells and 3.7 IU/mg by the radioimmunoassay technique. The natural hormone has a potency of 23--25 IU/mg by both assay methods.